Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant

Lendava Biologics Facility Is Expected To Become Fully Operational By 2026

Executive Summary

Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.

You may also be interested in...



Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab

Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.

Sandoz Unveils Further Biosimilars Investment

On the back of recently-announced initiatives and alliances to bolster its biosimilars business ahead of its upcoming spinoff from parent company Novartis, Sandoz has revealed a further investment of around $90m to construct a technical development center in Slovenia.

Sandoz Lifted By Growth In Europe And Biosimilars

Double-digit growth in the Europe region and in its biosimilars business helped to push up sales for Sandoz in the second quarter and first half of 2023.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel